XBiotech (XBIT) News Today $7.21 +0.51 (+7.61%) (As of 09/27/2024 08:51 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63September 21, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.22XBiotech (NASDAQ:XBIT) Stock Passes Above 50 Day Moving Average of $6.22August 14, 2024 | marketbeat.comXBIT Stock Earnings: XBiotech Reported Results for Q2 2024August 13, 2024 | investorplace.comXBiotech Inc. (NASDAQ:XBIT) most popular amongst retail investors who own 51%, insiders hold 35%August 3, 2024 | finance.yahoo.comXBiotech (NASDAQ:XBIT) Stock Crosses Above 50 Day Moving Average of $6.35XBiotech (NASDAQ:XBIT) Share Price Passes Above 50-Day Moving Average of $6.35August 3, 2024 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Sees Significant Increase in Short InterestXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 946,100 shares, a growth of 68.0% from the June 30th total of 563,100 shares. Approximately 4.8% of the company's stock are short sold. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is presently 7.2 days.July 26, 2024 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Sees Large Decrease in Short InterestXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totalling 563,100 shares, a drop of 14.3% from the June 15th total of 657,300 shares. Approximately 2.9% of the shares of the stock are short sold. Based on an average trading volume of 133,100 shares, the short-interest ratio is presently 4.2 days.July 14, 2024 | marketbeat.comXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerJune 18, 2024 | globenewswire.comXBiotech Inc. (XBIT)May 25, 2024 | finance.yahoo.comXBiotech: Several Shots On Goal In Big Target Market IndicationsMay 24, 2024 | seekingalpha.comXBIT Stock Earnings: XBiotech Reported Results for Q1 2024May 13, 2024 | investorplace.comXBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo FinanceApril 25, 2024 | finance.yahoo.comXBiotech IncApril 24, 2024 | money.usnews.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersMarch 20, 2024 | finance.yahoo.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 18, 2024 | investorplace.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 35.4% in FebruaryXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 537,500 shares, an increase of 35.4% from the February 14th total of 397,000 shares. Currently, 2.7% of the company's shares are sold short. Based on an average daily trading volume, of 36,700 shares, the short-interest ratio is presently 14.6 days.March 14, 2024 | marketbeat.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechMarch 8, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comXBiotech (NASDAQ:XBIT) Shares Cross Above 50 Day Moving Average of $4.56XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average of $4.56February 15, 2024 | marketbeat.comXBiotech (NASDAQ:XBIT) Stock Price Passes Above Fifty Day Moving Average of $4.37XBiotech (NASDAQ:XBIT) Shares Cross Above 50 Day Moving Average of $4.37February 7, 2024 | marketbeat.comXBiotech (NASDAQ:XBIT) Research Coverage Started at StockNews.comStockNews.com initiated coverage on XBiotech in a report on Wednesday. They issued a "sell" rating on the stock.February 7, 2024 | marketbeat.comXBiotech Inc XBITJanuary 18, 2024 | morningstar.comA top Austin biopharmaceutical company is doubling down on its Austin campusJanuary 8, 2024 | bizjournals.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusJanuary 4, 2024 | finance.yahoo.comARCT, EHTH and CRTO are among after hour moversDecember 15, 2023 | msn.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthDecember 5, 2023 | finance.yahoo.comXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finanznachrichten.deDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 72.4% in SeptemberXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 254,400 shares, an increase of 72.4% from the August 31st total of 147,600 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily volume of 21,400 shares, the short-interest ratio is presently 11.9 days.September 28, 2023 | marketbeat.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeSeptember 26, 2023 | finance.yahoo.comXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finanznachrichten.deXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyJune 30, 2023 | thestreet.comStockNews.com Initiates Coverage on XBiotech (NASDAQ:XBIT)StockNews.com began coverage on shares of XBiotech in a research report on Friday. They issued a "hold" rating for the company.June 2, 2023 | marketbeat.comXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 23, 2023 | finanznachrichten.deFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finanznachrichten.deXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finanznachrichten.deXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersApril 9, 2023 | finance.yahoo.comXBiotech (NASDAQ:XBIT) Earns Hold Rating from Analysts at StockNews.comStockNews.com started coverage on XBiotech in a research note on Tuesday. They set a "hold" rating for the company.April 4, 2023 | marketbeat.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableFebruary 15, 2023 | finance.yahoo.comXBiotech (NASDAQ:XBIT) Cut to Sell at StockNews.comStockNews.com cut XBiotech from a "hold" rating to a "sell" rating in a report on Tuesday.November 15, 2022 | marketbeat.comShort Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 42.4%XBiotech Inc. (NASDAQ:XBIT - Get Rating) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 96,100 shares, a growth of 42.4% from the October 15th total of 67,500 shares. Based on an average daily volume of 42,800 shares, the short-interest ratio is currently 2.2 days. Approximately 0.6% of the shares of the company are sold short.November 12, 2022 | marketbeat.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)November 11, 2022 | finance.yahoo.comInsiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyOctober 31, 2022 | finance.yahoo.comHelicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR NewswireOctober 18, 2022 | prnewswire.comXBiotech (NASDAQ:XBIT) Lowered to "Sell" at StockNews.comStockNews.com lowered shares of XBiotech from a "hold" rating to a "sell" rating in a research report on Tuesday.October 18, 2022 | marketbeat.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo FinanceOctober 13, 2022 | finance.yahoo.com Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address It’s over. (Ad)We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used by EVERY single AI company on the planet... AMD, NVIDIA, META... none of these companies could exist without this firm. Click here for the ticker >>> XBIT Media Mentions By Week XBIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XBIT News Sentiment▼1.890.72▲Average Medical News Sentiment XBIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XBIT Articles This Week▼10▲XBIT Articles Average Week Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DNTH News Today TNGX News Today AVBP News Today ABUS News Today RAPP News Today ETNB News Today HUMA News Today ORIC News Today SRRK News Today ATXS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XBIT) was last updated on 9/30/2024 by MarketBeat.com Staff From Our PartnersWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.